Belgium (BE)

Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci (2017) Kar SP, Adler E, Tyrer J, Hazelett D, Anton-Culver H, Bandera EV, Beckmann M, et al. Journal article Genetic modifiers of CHEK2*1100delC-associated breast cancer risk (2017) Muranen TA, Greco D, Blomqvist C, Aittomaki K, Khan S, Hogervorst F, Verhoef S, et al. Journal article Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium (2017) Barrdahl M, Rudolph A, Hopper JL, Southey MC, Broeks A, Fasching P, Beckmann M, et al. Journal article Body mass index and breast cancer survival: a Mendelian randomization analysis (2017) Guo Q, Burgess S, Turman C, Bolla MK, Wang Q, Lush M, Abraham J, et al. Journal article BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer (2017) Shimelis H, Mesman RLS, Von Nicolai C, Ehlen A, Guidugli L, Martin C, Calleja FMGR, et al. Journal article Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci (2017) Glubb DM, Johnatty SE, Quinn MCJ, O'Mara TA, Tyrer JP, Gao B, Fasching P, et al. Journal article TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer (2017) Fagerholm R, Khan S, Schmidt MK, Garcia-Closas M, Heikkila P, Saarela J, Beesley J, et al. Journal article Impact of combined sodium chloride and saturated long-chain fatty acid challenge on the differentiation of T helper cells in neuroinflammation (2017) Hammer A, Schliep A, Joerg S, Haghikia A, Gold R, Kleinewietfeld M, Mueller DN, Linker R Journal article STRUCTURAL DAMAGE PROGRESSION IN PATIENTS TREATED WITH METHOTREXATE, BARICITINIB MONOTHERAPY OR BARICITINIB plus METHOTREXATE BASED ON THEIR LEVEL OF CLINICAL RESPONSE IN THE PHASE 3 RA-BEGIN STUDY (2017) Van Der Heijde D, Durez P, Schett G, Naredo E, Ostergaard M, Meszaros G, Bello N, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL (2017) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution